[go: up one dir, main page]

TW200736258A - Pyrimidine derivatives for the treatment of abnormal cell growth - Google Patents

Pyrimidine derivatives for the treatment of abnormal cell growth

Info

Publication number
TW200736258A
TW200736258A TW095147907A TW95147907A TW200736258A TW 200736258 A TW200736258 A TW 200736258A TW 095147907 A TW095147907 A TW 095147907A TW 95147907 A TW95147907 A TW 95147907A TW 200736258 A TW200736258 A TW 200736258A
Authority
TW
Taiwan
Prior art keywords
treatment
cell growth
abnormal cell
pyrimidine derivatives
mammals
Prior art date
Application number
TW095147907A
Other languages
English (en)
Inventor
Joel Thomas Arcari
Samit Kumar Bhattacharya
Arthur Douglas Brosius
Michael Joseph Luzzio
Kendra Louise Nelson
Gonghua Pan
Southers, Jr
Donn Gregory Wishka
Jun Xiao
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TW200736258A publication Critical patent/TW200736258A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
TW095147907A 2005-12-21 2006-12-20 Pyrimidine derivatives for the treatment of abnormal cell growth TW200736258A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75270805P 2005-12-21 2005-12-21

Publications (1)

Publication Number Publication Date
TW200736258A true TW200736258A (en) 2007-10-01

Family

ID=38038639

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095147907A TW200736258A (en) 2005-12-21 2006-12-20 Pyrimidine derivatives for the treatment of abnormal cell growth

Country Status (30)

Country Link
US (1) US7820648B2 (zh)
EP (1) EP1966207A2 (zh)
JP (1) JP4332590B2 (zh)
KR (1) KR101060051B1 (zh)
CN (1) CN101346380B (zh)
AP (1) AP2008004488A0 (zh)
AR (1) AR058399A1 (zh)
AU (1) AU2006327871A1 (zh)
BR (1) BRPI0620324A2 (zh)
CA (1) CA2634646C (zh)
CR (1) CR10095A (zh)
DO (1) DOP2006000289A (zh)
EA (1) EA014551B1 (zh)
EC (1) ECSP088563A (zh)
GT (1) GT200600517A (zh)
HN (1) HN2006042221A (zh)
IL (1) IL191555A0 (zh)
MA (1) MA30075B1 (zh)
ME (1) MEP0908A (zh)
NL (1) NL2000375C2 (zh)
NO (1) NO20082338L (zh)
PE (1) PE20071138A1 (zh)
RS (1) RS20080272A (zh)
SV (1) SV2008002969A (zh)
TN (1) TNSN08270A1 (zh)
TW (1) TW200736258A (zh)
UA (1) UA89123C2 (zh)
UY (1) UY30051A1 (zh)
WO (1) WO2007072158A2 (zh)
ZA (1) ZA200804488B (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122542B2 (en) 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
JP2009542604A (ja) * 2006-07-06 2009-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ４−ヘテロシクロアルキルピリミジン、それらの調製方法及び医薬としての使用
JP5512274B2 (ja) * 2006-10-23 2014-06-04 セファロン、インク． ＡＬＫ阻害剤およびｃ−ＭＥＴ阻害剤としての２，４−ジアミノピリミジンの縮合二環式誘導体
JP4782239B2 (ja) 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
CA2693594A1 (en) 2007-07-17 2009-01-22 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
EP2231620A1 (en) * 2007-12-03 2010-09-29 Boehringer Ingelheim International GmbH Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
CA2718858A1 (en) * 2008-03-20 2009-09-24 Boehringer Ingelheim International Gmbh Selective synthesis of substituted pyrimidines
UY31714A (es) * 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
ES2472323T3 (es) 2008-06-17 2014-06-30 Astrazeneca Ab Compuestos de piridina
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
TW201100441A (en) * 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
WO2011018517A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
TWI513694B (zh) 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
WO2011144742A1 (en) 2010-05-21 2011-11-24 Chemilia Ab Novel pyrimidine derivatives
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
PT2646448T (pt) 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Inibidores macrocíclicos de cinases
EP2688883B1 (en) 2011-03-24 2016-05-18 Noviga Research AB Pyrimidine derivatives
RU2586333C1 (ru) 2011-12-09 2016-06-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные 4-гидрокси-1,2,3,4-тетрагидронафталин-1-ил-мочевины и их применение в лечении, среди прочего, заболеваний дыхательного тракта
AU2012357038B2 (en) 2011-12-23 2016-05-12 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
CN103655577A (zh) * 2012-09-20 2014-03-26 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103664957A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
CN105130907B (zh) * 2015-07-29 2018-10-16 沈阳药科大学 嘧啶类化合物及其用途
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
WO2020023851A1 (en) * 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
WO2022147620A1 (en) * 2021-01-07 2022-07-14 Ontario Institute For Cancer Research (Oicr) Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof
EP4277902A4 (en) * 2021-01-07 2024-12-18 Ontario Institute for Cancer Research (OICR) ISOINDOLINONE-AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
WO2004048343A1 (en) 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EP1590334B1 (en) 2003-01-30 2009-08-19 Boehringer Ingelheim Pharmaceuticals Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
WO2005111023A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111016A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
CA2634646A1 (en) 2007-06-28
MA30075B1 (fr) 2008-12-01
UY30051A1 (es) 2007-07-31
CR10095A (es) 2008-07-17
KR101060051B1 (ko) 2011-08-29
CN101346380A (zh) 2009-01-14
DOP2006000289A (es) 2007-07-31
NL2000375C2 (nl) 2008-01-03
RS20080272A (sr) 2009-07-15
US20080234303A1 (en) 2008-09-25
WO2007072158A3 (en) 2007-12-27
UA89123C2 (ru) 2009-12-25
CA2634646C (en) 2012-04-10
SV2008002969A (es) 2010-08-17
EA014551B1 (ru) 2010-12-30
AP2008004488A0 (en) 2008-06-30
JP2009520807A (ja) 2009-05-28
JP4332590B2 (ja) 2009-09-16
AU2006327871A1 (en) 2007-06-28
GT200600517A (es) 2007-09-13
WO2007072158A2 (en) 2007-06-28
EA200801287A1 (ru) 2008-10-30
ZA200804488B (en) 2009-05-27
US7820648B2 (en) 2010-10-26
IL191555A0 (en) 2008-12-29
AR058399A1 (es) 2008-01-30
PE20071138A1 (es) 2007-12-29
WO2007072158A8 (en) 2008-08-14
HN2006042221A (es) 2010-01-18
NO20082338L (no) 2008-06-25
TNSN08270A1 (fr) 2009-10-30
NL2000375A1 (nl) 2007-06-25
MEP0908A (xx) 2010-02-10
ECSP088563A (es) 2008-07-30
CN101346380B (zh) 2012-02-29
KR20080077026A (ko) 2008-08-20
BRPI0620324A2 (pt) 2011-11-08
EP1966207A2 (en) 2008-09-10

Similar Documents

Publication Publication Date Title
TW200736258A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
TW200607801A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
TW200612949A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06013164A (es) Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
MY142109A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MY148636A (en) Benzimidazole derivatives
MX2009011090A (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal.
WO2009155121A3 (en) Inhibitors of pi3 kinase
CA2510853A1 (en) Pyrrolopyrimidine derivatives
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
MY139399A (en) Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
WO2007044724A3 (en) Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3
UA99447C2 (ru) Способ получения силденафила
WO2005070884A3 (en) Heterocyclic compounds useful as growth hormone secretagogues
TW200420541A (en) Crystalline forms
PT2049480E (pt) Derivados de 2-arilindole como inibidores da mpges-i
WO2006116733A3 (en) Protein kinase inhibitors
JO2413B1 (en) Benzoxazine derivatives and their use
TW200639159A (en) Treatment of pain
EA200601796A1 (ru) Пиримидиновые производные для лечения аномального клеточного роста
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
TW200505869A (en) Thiophenylaminoimidazolines
TW200637861A (en) Novel diazabicyclononene derivative